The GLP-1 track continues to heat up, and Semaglutide (910463-68-2) has made multiple breakthroughs, empowering metabolic health and multi-field scientific research innovation
In recent years, the global GLP-1 (glucagon-like peptide-1) receptor agonist field has continued to explode. As a core benchmark product in this field, Semaglutide (CAS number: Semaglutide) With its clear therapeutic effect, wide application scenarios and continuously expanding scientific research value, 910463-68-2) has become a focus in the fields of pharmaceutical research and development, clinical application and chemical production, promoting metabolic health treatment and multidisciplinary research into a new stage.
Semaglutide is an artificially synthesized long-acting GLP-1 receptor agonist, belonging to the polypeptide compound class. Its chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of approximately 4113.6 and a purity of over 98.0%. It appears as a white powder and is highly soluble in water. At room temperature, it should be stored in a sealed container away from light to ensure its activity. Compared with endogenous GLP-1 in the human body, Semaglutide achieves long-lasting effects through two key structural modifications:
In the field of clinical application, the core value of Semaglutide has been fully verified by numerous clinical trials worldwide. As an important drug for the treatment of type 2 diabetes, it effectively reduces the level of glycated hemoglobin (HbA1c) in patients by promoting insulin secretion in a glucose-dependent manner, inhibiting glucagon release, and delaying gastric emptying. The SUSTAIN series of clinical trials have shown that A administration dose of 0.5-1.0 mg once a week can reduce HbA1c by 1.5%-1.8%, and the risk of hypoglycemia is relatively low. Meanwhile, its remarkable weight loss effect has become an important breakthrough in the treatment of obesity. The STEP series of studies have shown that a dose of 2.4mg per week can reduce the weight of non-diabetic obese patients by 15% to 18% and the visceral fat by more than 40%, providing a new treatment option for obese and overweight people. In addition, Semaglutide has been confirmed to have a cardiovascular protective effect, which can reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes complicated with cardiovascular diseases, further expanding its clinical application boundaries.
In addition to its mature clinical applications, the scientific research potential of Semaglutide is continuously being explored, and its application fields are constantly expanding. Research has found that this compound can penetrate the blood-brain barrier and exhibit neuroprotective effects in models of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. It can inhibit the aggregation of α -synuclein and alleviate neuroinflammation, providing a new direction for the study of such diseases. In the research on the treatment of metabolism-related fatty liver disease (MASLD), Semaglutide inhibits liver fat regeneration by regulating key enzymes in lipid metabolism. Phase II clinical trials have shown that 48-week treatment can reduce liver fat content by 40% to 50%, bringing new hope for the treatment of liver diseases. In addition, it also shows potential value in the research of cancers such as breast cancer and colorectal cancer. It can slow down the proliferation of cancer cells by inhibiting related signaling pathways, providing new ideas for the cross-disciplinary research of cancer and metabolism.
On the industrial side, with the rapid expansion of the global GLP-1 market, the production and supply capacity of Semaglutide has continued to improve. According to industry data, the global GLP-1 market size is expected to reach approximately 52.83 billion US dollars in 2024, representing a year-on-year growth of 46%. Among this, Semaglutide's sales are about 29.3 billion US dollars, accounting for 55.5%. It is projected that the global GLP-1 market size will exceed 150 billion US dollars by 2030. Semaglutide will still occupy a core position. At present, many domestic enterprises have achieved industrial production of Semaglutide raw materials. Some enterprises have also obtained DMF registration for both "recombinant" and "total synthesis" manufacturing processes. The product purity is over 99%, and the technology is at the international leading level. Meanwhile, it supports various modifications such as biotin labeling and fluorescence labeling, meeting personalized scientific research needs. With the core patent of Semaglutide expiring in 2026, domestic pharmaceutical companies have been actively laying out the research and development of similar drugs, further promoting the localization process of this product and helping it benefit more patients and research institutions.
Industry experts say that the rise of Semaglutide (910463-68-2) has not only reshaped the treatment landscape of metabolic diseases, but also promoted the iterative upgrading of peptide drug research and development technology. Its extension from clinical treatment to multi-field scientific research highlights the great potential of GLP-1 receptor agonists. In the future, with the continuous deepening of scientific research and the continuous optimization of production technology, Semaglutide will achieve breakthroughs in more fields such as metabolic health, neuroprotection, and tumor research. At the same time, the acceleration of the domestic production process will further reduce its application cost, injecting new impetus into the high-quality development of the global pharmaceutical and health industry.
It is reported that a complete Semaglutide supply chain system has been formed in the current market, covering multiple links such as raw material production, formulation research and development, and supply of scientific research reagents. Relevant enterprises ensure that their products meet international standards through strict quality control systems, providing reliable support for clinical applications and scientific research work, and contributing to the continuous progress of global medical research and health.